Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

The impact of de novo liver metastasis on clinical outcome in patients with advanced non-small-cell lung cancer.

PloS one - 1 Jan 2017

Chang Yu-Ping, Chen Yu-Mu, Lai Chien-Hao, Lin Chiung-Yu, Fang Wen-Feng, Huang Cherng-Hua, Li Shau-Hsuan, Chen Hung-Chen, Wang Chin-Chou, Lin Meng-Chih

Abstract excerpt

Liver metastasis has been found to affect outcome in prostate cancer and colorectal cancer, but its role in lung cancer is unclear. The current study aimed to evaluate the impact of de novo liver metastasis (DLM) on stage IV non-small cell lung cancer (NSCLC) outcomes and to examine whether tyrosine kinase inhibitors (TKI) reverse poor prognosis in patients with DLM and epidermal growth factor receptor...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Carcinoma, Non-Small-Cell Lung
Share to Disease-Free Survival

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to ErbB Receptors

Share to EGFR gene

Share to Liver Neoplasms

Share to Lung Neoplasms

Share to Mutation

Share to Treatment Outcome

Source

Open in PubMed Open full text

Identifiers

PMID: 28591157
DOI: 10.1371/journal.pone.0178676
PMCID: PMC5462397

Genes

EGFR

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

The impact of de novo liver metastasis on clinical outcome in patients with advanced non-small-cell lung cancer.PMID 28591157Read ↗

Characterization of Liver Metastasis and Its Effect on Targeted Therapy in EGFR-mutant NSCLC: A Multicenter Study.Semantic proximity Read ↗

Liver metastasis predicts poorer prognosis in stage IV lung adenocarcinoma patients receiving first-line gefitinib.Semantic proximity Read ↗

Impact of epidermal growth factor receptor (EGFR) activating mutations and their targeted treatment in the prognosis of stage IV non-small cell lung cancer (NSCLC) patients harboring liver metastasis.Semantic proximity Read ↗

Brain parenchymal and leptomeningeal metastasis in non-small cell lung cancer.Semantic proximity Read ↗

Brain parenchymal and leptomeningeal metastasis in lung cancerSemantic proximity Read ↗

Hepatic metastasis is a poor predictive marker for erlotinib in lung adenocarcinoma.Semantic proximity Read ↗

Analysis of non-small cell lung cancer with miliary lung metastasis in patients harboring epidermal growth factor receptor mutations.Semantic proximity Read ↗

Efficacy and safety of first-line EGFR-TKI combined with chemotherapy versus EGFR-TKI monotherapy in patients with EGFR-mutant non-small cell lung cancer and liver metastases: A propensity score-matched analysis.Semantic proximity Read ↗

Presence of liver metastasis correlated with high tumor abundance and indicated adverse prognostic feature in EGFR mutation non-small-cell lung cancer patients.Semantic proximity Read ↗

Dynamic liver dysfunction predicts poor survival in patients with EGFR-mutant non-small cell lung cancer and liver metastases treated with EGFR tyrosine kinase inhibitors.Semantic proximity Read ↗

Number of liver metastatic nodules affects treatment options for pulmonary adenocarcinoma patients with liver metastases.Semantic proximity Read ↗

Miliary metastases are associated with epidermal growth factor receptor mutations in non-small cell lung cancer: a population-based study.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.